NDA 018771 · Bausch and Lomb INC
Lacrisert
Hydroxypropyl Cellulose · Ophthalmic
DiscontinuedLast checked: Nov 20, 2026Latest source record: Oct 30, 2008 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1981
Jun 1, 1981
Approved uses
1
Original approval plus efficacy supplements
Registered trials
82
17 Phase 3, 6 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 1, 1981 Original approval · Type 3 - New Dosage Form
1 products under this application
- LACRISERT · HYDROXYPROPYL CELLULOSE 5MG · INSERT, OPHTHALMIC · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Hydroxypropyl Cellulose" as an intervention, any sponsor and status, largest first.
- Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive ParticipantsPivotal-lookingActive, not recruiting
ViiV HealthcareGSK (GSK)
NCT02938520 · 631 participants · Start Oct 27, 2016 · Primary completion Aug 30, 2018
Drug: Cabotegravir (CAB) tablet; Rilpivirine (RPV) tablet and 4 more · For: HIV Infections
Sites: Birmingham, Alabama; Bakersfield, California; Long Beach, California · 108 sites in all
- Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected AdultsPivotal-lookingActive, not recruiting
ViiV HealthcareGSK (GSK)
NCT02951052 · 618 participants · Start Oct 28, 2016 · Primary completion May 29, 2018
Drug: Cabotegravir (CAB) tablet; Rilpivirine (RPV) tablet and 3 more · For: Infection, Human Immunodeficiency Virus; HIV Infections
Sites: Birmingham, Alabama; Phoenix, Arizona; Bakersfield, California · 113 sites in all
- Study of the Safety and Effectiveness of Esmirtazapine in Participants With Chronic Primary Insomnia (P05706)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00482612 · 526 participants · Start Dec 7, 2006 · Primary completion Aug 11, 2008
Drug: Esmirtazapine; Placebo · For: Insomnia
- MORDOR II Burkina Faso: Longitudinal TrialPivotal-lookingCompleted
University of California, San FranciscoAcademic, hospital or other
NCT03676751 · 500 participants · Start Oct 10, 2019 · Primary completion Jul 6, 2020
Drug: Azithromycin; Placebo · For: Child Growth; Diversity of Microbiome; Child Mortality and 1 more
Sites: Nouna, Burkina Faso
- Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial CancerPivotal-lookingNot yet recruiting
Evergreen Therapeutics, Inc.Industry
NCT05077215 · 450 participants (planned) · Start Dec 2026 · Primary completion Dec 2027
Drug: EG-007; Pembrolizumab 100 mg/ 4 ml (25 mg/ml) Injection and 1 more · For: Advanced Endometrial Cancer
- Gut and Azithromycin Mechanisms in Infants and Children IIPivotal-lookingCompleted
University of California, San FranciscoAcademic, hospital or other
NCT04315272 · 449 participants · Start Aug 21, 2020 · Primary completion Jun 1, 2022
Drug: Azithromycin; Placebo · For: Malaria
Sites: Nouna, Burkina Faso
- A Six Week, Double-Blind Randomized, Efficacy and Safety, Sleep Lab Trial With Esmirtazapine (Org 50081) (P05707)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00506389 · 419 participants · Start Jun 6, 2007 · Primary completion Feb 13, 2008
Drug: Esmirtazapine; Placebo · For: Insomnia
- A Study of KL590586 in Patients With Advanced Solid TumorsActive, not recruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Industry
NCT05265091 · 414 participants (planned) · Start Sep 15, 2021 · Primary completion Dec 31, 2026
Drug: KL590586 Capsule · For: Advanced Solid Tumor
Sites: Chengdu, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Adhesive tablet effective for treating canker sores in humans.
Mizrahi B, Golenser J, Wolnerman JS, et al. · J Pharm Sci 2004 · Clinical Trial, Comparative Study
- Randomised clinical trial: colestyramine vs. hydroxypropyl cellulose in patients with functional chronic watery diarrhoea.
Fernández-Bañares F, Rosinach M, Piqueras M, et al. · Aliment Pharmacol Ther 2015 · Clinical Trial, Phase IV, Comparative Study
- Performance of a hydroxypropyl cellulose film former in normal and ulcerated oral mucosa.
Rodu B, Russell CM · Oral Surg Oral Med Oral Pathol 1988 · Clinical Trial, Comparative Study
- Effect of excipients on the particle size of precipitated pioglitazone in the gastrointestinal tract: impact on bioequivalence.
Sugita M, Kataoka M, Sugihara M, et al. · AAPS J 2014 · Randomized Controlled Trial
- Gastric ulcer treatment with intravenous human epidermal growth factor: a double-blind controlled clinical study.
Itoh M, Matsuo Y · J Gastroenterol Hepatol 1994 · Clinical Trial, Comparative Study
- A combination of hydroxypropyl cellulose and trehalose as supplementation for vitrification of human oocytes: a retrospective cohort study.
Coello A, Campos P, Remohí J, et al. · J Assist Reprod Genet 2016 · Controlled Clinical Trial
Sponsor: Bausch and Lomb INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.